Prior studies have implicated these TRIP13 targets in the progression of various cancers, including COL6A3 [44, 45] and KLK7 [46] in CRCs, SHC3 in hepatocellular carcinomas [47], and TREM2 in gastric cancers [48] and renal cell carcinomas [49]. Here, COL6A3 is linked to renal cell carcinoma.